Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential

被引:77
作者
Demidenko, Zoya N.
Blagosklonny, Mikhail V. [1 ]
机构
[1] Roswell Pk Canc Inst, Dept Cell Stress Biol, BLSC, Buffalo, NY 14263 USA
来源
AGING-US | 2009年 / 1卷 / 12期
关键词
cellular senescence; cellular hypertrophy; aging-suppression; rapamycin; mTOR; CELLS; ARREST; INHIBITION; SECRETION; RAPAMYCIN; PROTEIN; CANCER; LEADS;
D O I
10.18632/aging.100115
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Development of agents that suppress aging (aging suppressants) requires quantification of cellular senescence. Cellular senescence in vitro is characterized by a large cell morphology and permanent loss of proliferative potential. When HT-1080 cells were arrested by p21, they continued to grow exponentially in size and became hypertrophic with a 15-fold increase in the protein content per cell. These changes were mirrored by accumulation of GFP ( driven by CMV promoter) per cell, which also served as a marker of cellular hypertrophy. Preservation of proliferative potential ( competence) was measured by an increase in live cell number, when p21 was switched off. While modestly decreasing hypertrophy in p21-arresrted cells, rapamycin considerably preserved competence, converting senescence into quiescence. Preservation of proliferative potential ( competence) correlated with inhibition of S6 phosphorylation by rapamycin. When p21 was switched off, competent cells, by resuming proliferation, became progressively less hypertrophic. Preservation of proliferative potential is a sensitive and quantitative measure of suppression of mTOR-driven senescence.
引用
收藏
页码:1008 / 1016
页数:9
相关论文
共 31 条
  • [1] Control of senescence by CXCR2 and its ligands
    Acosta, Juan C.
    O'Loghlen, Ana
    Banito, Ana
    Raguz, Selina
    Gil, Jesus
    [J]. CELL CYCLE, 2008, 7 (19) : 2956 - 2959
  • [2] MicroRNAs miR-146a/b negatively modulate the senescence associated inflammatory mediators IL-6 and IL-8
    Bhaumik, Dipa
    Scott, Gary K.
    Schokrpur, Shiruyeh
    Patil, Christopher K.
    Orjalo, Arturo V.
    Rodier, Francis
    Lithgow, Gordon J.
    Campisi, Judith
    [J]. AGING-US, 2009, 1 (04): : 402 - 411
  • [3] Prevention of cancer by inhibiting aging
    Blagosklonny, Mikhail V.
    [J]. CANCER BIOLOGY & THERAPY, 2008, 7 (10) : 1520 - 1524
  • [4] Aging, stem cells, and mammalian target of rapamycin: A prospect of pharmacologic rejuvenation of aging stem cells
    Blagosklonny, Mikhail V.
    [J]. REJUVENATION RESEARCH, 2008, 11 (04) : 801 - 808
  • [5] An anti-aging drug today: from senescence-promoting genes to anti-aging pill
    Blagosklonny, Mikhail V.
    [J]. DRUG DISCOVERY TODAY, 2007, 12 (5-6) : 218 - 224
  • [6] Aging and immortality - Quasi-programmed senescence and its pharmacologic inhibition
    Blagosklonny, Mikhail V.
    [J]. CELL CYCLE, 2006, 5 (18) : 2087 - 2102
  • [7] Cell senescence: Hypertrophic arrest beyond the restriction point
    Blagosklonny, Mikhail V.
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2006, 209 (03) : 592 - 597
  • [8] Validation of anti-aging drugs by treating age-related diseases
    Blagosklonny, Mikhail V.
    [J]. AGING-US, 2009, 1 (03): : 281 - 288
  • [9] Aging-suppressants Cellular senescence (hyperactivation) and its pharmacologic deceleration
    Blagosklonny, Mikhail V.
    [J]. CELL CYCLE, 2009, 8 (12) : 1883 - 1887
  • [10] Cell senescence and hypermitogenic arrest
    Blagosklonny, MV
    [J]. EMBO REPORTS, 2003, 4 (04) : 358 - 362